Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Quintessence Biosciences Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting

Abstract:
Quintessence today announced that data for their lead EVade™ Ribonuclease, called QBI-139, will be presented at the American Society of Clinical Oncology 46th Annual Meeting.

Quintessence Biosciences Presents Human Ribonuclease Variant, QBI-139, at the American Society of Clinical Oncology Meeting

Madison, WI | Posted on June 7th, 2010

QBI-139 is a protein therapeutic that targets the RNA in cancer cells. The data from abstract TPS162 will be presented at 8 AM on Monday June 7, 2010. The focus will be on the design of the Phase I clinical trial of QBI-139. QBI-139 has shown broad single agent activity against a variety of cancer models addressing significant unmet need, such as non-small cell lung and pancreatic cancers.

####

About Quintessence Biosciences
Quintessence Biosciences, Inc. is a private biopharmaceutical company focused on development of cancer therapies based on the proprietary EVade™ Ribonuclease technology. Quintessence’s first product candidate, QBI- 139, is in a Phase 1 clinical trial at The University of Texas M.D. Anderson Cancer Center and The University of Wisconsin Carbone Cancer Center. The company also has a pipeline of other EVade™ Ribonuclease products in preclinical research. For more information, visit www.quintbio.com.

About the American Society of Clinical Oncology
The 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) is being held in Chicago, June 4-8, 2010. This year's Annual Meeting will focus on Advancing Quality through Innovation. More than 30,000 cancer specialists from around the world will gather to discuss the latest innovations in research, quality, practice and technology in cancer. For more information, visit chicago2010.asco.org/Home.aspx

About the ASCO Annual Meeting Trials in Progress Poster Session
The objective of the Trials in Progress Poster Session is to publicize ongoing phase I or phase II trials and stimulate discussion and participation among peers. The posters discuss the science behind the trial, including pre-clinical data. In addition, the posters will describe the trial design and current enrollment status.

For more information, please click here

Contacts:
Dr. Laura Strong
President and Chief Operating Officer
608-441-2950


Copyright © Quintessence Biosciences

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Controlling phase changes in solids: Controlling phase changes in solids July 29th, 2015

Liquipel Debuts Eyesight-Saving ION-Glass Blue Light Protection for iPhones and Androids at RadioShack Stores Nationwide: Liquipel's Unique Protective Screen, Available at RadioShack, Cuts Harmful Blue Light Implicated in Macular Degeneration by 10x July 28th, 2015

Nanophase to present paper on slurry pH impact at Optics + Photonics conference July 28th, 2015

Laboratorial Performance of Nanocomposite Membrane Improved in Water Purification July 28th, 2015

Nanomedicine

Stretching the limits on conducting wires July 25th, 2015

UT Dallas nanotechnology research leads to super-elastic conducting fibers July 24th, 2015

Nanopaper as an optical sensing platform July 23rd, 2015

Albany College of Pharmacy and Health Sciences to Host One Week Symposium on Nanomedicine July 23rd, 2015

Announcements

Controlling phase changes in solids: Controlling phase changes in solids July 29th, 2015

Perfect Optical Properties in Production of Aluminum Oxide Colloid Nanoparticles July 28th, 2015

Short wavelength plasmons observed in nanotubes: Berkeley Lab researchers create Ludinger liquid plasmons in metallic SWNTs July 28th, 2015

'Seeing' molecular interactions could give boost to organic electronics July 28th, 2015

Events/Classes

Photonex 2015 - The 3rd biennial Optical Metrology meeting is announced with an exciting number of speakers from across Europe July 28th, 2015

Nanometrics Announces Upcoming Investor Events July 28th, 2015

Nanophase to present paper on slurry pH impact at Optics + Photonics conference July 28th, 2015

Albany College of Pharmacy and Health Sciences to Host One Week Symposium on Nanomedicine July 23rd, 2015

Nanobiotechnology

New computer model could explain how simple molecules took first step toward life: Two Brookhaven researchers developed theoretical model to explain the origins of self-replicating molecules July 28th, 2015

Spintronics: Molecules stabilizing magnetism: Organic molecules fixing the magnetic orientation of a cobalt surface/ building block for a compact and low-cost storage technology/ publication in Nature Materials July 25th, 2015

Programming adult stem cells to treat muscular dystrophy and more by mimicking nature July 22nd, 2015

Biophotonics - Global Strategic Business Report 2015 July 21st, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project